Ann Oncol
- PASSARO A, Wang J, Shah S, Bauml JM, et al
Letter to the Editor regarding 'Correspondence to: Amivantamab plus chemotherapy
with and without lazertinib in EGFR-mutant advanced NSCLC after disease
progression on osimertinib: primary results from the phase III MARIPOSA-2 study'
by Moik F, Riedl
Ann Oncol. 2024;35:328-329.
- MOIK F, Riedl JM, Ay C
Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in
EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary
results from the phase III MARIPOSA-2 study.
Ann Oncol. 2024;35:327.
Anticancer Res
- INOMATA M, Minatoyama S, Takata N, Hayashi K, et al
Immune Checkpoint Inhibitor Therapy for Patients With Non-small Cell Lung Cancer
Ineligible for Platinum Doublet Chemotherapy.
Anticancer Res. 2024;44:1241-1245.
- KINOSHITA H, Kinoshita S, Kamoda H, Hagiwara Y, et al
Combined Auranofin and Celecoxib Suppresses the Local Progression and Pulmonary
Metastases of Osteosarcoma In Vivo.
Anticancer Res. 2024;44:1045-1049.
Arch Pathol Lab Med
- BLATNIK A, Dragos VS, Blatnik O, Stegel V, et al
A Population-Based Study of Patients With Small Cell Carcinoma of the Ovary,
Hypercalcemic Type, Encompassing a 30-Year Period.
Arch Pathol Lab Med. 2024;148:299-309.
BMC Cancer
- CHEN K, Li S, Chen M, Jin Z, et al
Endostar acts as a pneumonitis protectant in patients with locally advanced
non-small cell lung cancer receiving concurrent chemoradiotherapy.
BMC Cancer. 2024;24:257.
- WANG X, Zhao J, Mei T, Liu W, et al
Quantification of preexisting lung ground glass opacities on CT for predicting
checkpoint inhibitor pneumonitis in advanced non-small cell lung cancer patients.
BMC Cancer. 2024;24:269.
- XU M, Li C, Xiang L, Chen S, et al
Assessing the causal relationship between 731 immunophenotypes and the risk of
lung cancer: a bidirectional mendelian randomization study.
BMC Cancer. 2024;24:270.
Cancer
- TAN AC, Lai GGY, Saw SPL, Chua KLM, et al
Detection of circulating tumor DNA with ultradeep sequencing of plasma cell-free
DNA for monitoring minimal residual disease and early detection of recurrence in
early-stage lung cancer.
Cancer. 2024 Feb 29. doi: 10.1002/cncr.35263.
- MORGENSZTERN D
The expanding role of circulating tumor DNA in resectable non-small cell lung
cancer.
Cancer. 2024 Feb 29. doi: 10.1002/cncr.35268.
-
Erratum to "Patient-reported outcomes with cemiplimab monotherapy for first-line
treatment of advanced non-small cell lung cancer with PD-L1 of >/=50%: The
EMPOWER-Lung 1 study".
Cancer. 2024 Feb 23. doi: 10.1002/cncr.35165.
Cancer Cell
- TONG X, Patel AS, Kim E, Li H, et al
Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant
lung cancer.
Cancer Cell. 2024 Feb 20:S1535-6108(24)00036-9. doi: 10.1016/j.ccell.2024.
Cancer Lett
- HAN R, Lin C, Lu C, Wang Y, et al
Sialyltransferase ST3GAL4 confers osimertinib resistance and offers strategies to
overcome resistance in non-small cell lung cancer.
Cancer Lett. 2024;588:216762.
- MADORSKY ROWDO FP, Xiao G, Khramtsova GF, Nguyen J, et al
Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are
sensitive to synergistic combination PARP inhibitor treatment.
Cancer Lett. 2024;584:216608.
Cancer Sci
- KAJIWARA N, Kakihana M, Maeda J, Kaneko M, et al
Salivary metabolomic biomarkers for non-invasive lung cancer detection.
Cancer Sci. 2024 Feb 28. doi: 10.1111/cas.16112.
Clin Exp Metastasis
- WIEGMANS AP, Ivanova E, Naei VY, Monkman J, et al
Poor patient outcome correlates with active engulfment of cytokeratin positive
CTCs within cancer-associated monocyte population in lung cancer.
Clin Exp Metastasis. 2024 Feb 28. doi: 10.1007/s10585-024-10270.
Clin Lung Cancer
- BORGHETTI P, Facheris G, Ciammella P, Galaverni M, et al
Sterotactic Ablative Radiotherapy in a Multicentric Series of Oligometastatic
SCLC: The SAMOS Cohort.
Clin Lung Cancer. 2024;25:151-158.
- GONZALEZ-MOSQUERA LF, Rous FA, Rogers A, Smith N, et al
ALK Rearrangement Positive Lung Adenocarcinoma in Pregnancy Treated With
Alectinib: A Case Report.
Clin Lung Cancer. 2024;25:e77-e80.
- VERMA S, Young S, Kennedy TAC, Carvalhana I, et al
Detection of Circulating Tumor DNA After Stereotactic Ablative Radiotherapy in
Patients With Unbiopsied Lung Tumors (SABR-DETECT).
Clin Lung Cancer. 2024;25:e87-e91.
- JENNINGS EM, Camidge DR, Gadgeel S, Barker S, et al
Trial Design and Optimal Determination of CNS Activity of Small Molecule Targeted
Therapy in NSCLC.
Clin Lung Cancer. 2024;25:91-99.
- INNO A, Picece V, Bogina G, Settanni G, et al
Niraparib for the Treatment of Metastatic NSCLC in a Patient With BRCA2 Germinal
Mutation: A Case Report.
Clin Lung Cancer. 2024;25:175-179.
- ARDESHIR-LARIJANI F, Maniar R, Goyal S, Loehrer PJ, et al
Trop-2 Expression and Its Impact on Survival in Thymic Epithelial Tumors: Brief
Report.
Clin Lung Cancer. 2024;25:180-185.
- WALIANY S, Neal JW, Engel-Nitz N, Lam C, et al
HER2-Mutant Advanced and/or Metastatic Non-Small-Cell Lung Cancer: A US
Electronic Health Records Database Analysis of Clinical Characteristics,
Treatment Practice Patterns, and Outcomes.
Clin Lung Cancer. 2024 Jan 18:S1525-7304(24)00004.
- WU Y, Zhao Y, Wu Y, Chen H, et al
A Retrospective Real-World Study of Prognostic Factors Associated With EGFR
Mutated Lung Cancer With Leptomeningeal Metastasis.
Clin Lung Cancer. 2024 Feb 8:S1525-7304(24)00012.
Eur J Cardiothorac Surg
- WANG RR, Li MJ, Peng Q, Huang ZY, et al
Validation of the ninth edition of the TNM staging system for Non-Small cell lung
cancer with lobectomy in stage IA-IIIA.
Eur J Cardiothorac Surg. 2024 Feb 29:ezae071. doi: 10.1093.
- BARCELOS RR, Sugarbaker E, Kennedy KF, McAllister M, et al
Time between imaging and surgery is not a risk factor for upstaging of clinical
stage IA non-small-cell lung cancer.
Eur J Cardiothorac Surg. 2024;65:ezae057.
- GONZALEZ M, Ojanguren A, Figueroa S, Bedat B, et al
Segmentectomy for lung cancer: Dig deeper.
Eur J Cardiothorac Surg. 2024 Feb 24:ezae066. doi: 10.1093.
- BERNARDI E, Diotti C, Bertolaccini L, Donghi S, et al
Mediastinal cellulose pack mimicking lung cancer relapsing after lobectomy.
Eur J Cardiothorac Surg. 2024 Feb 23:ezae065. doi: 10.1093.
Int J Radiat Oncol Biol Phys
- LUCIA F, Bourhis D, Pinot F, Hamya M, et al
Prediction of Acute Radiation-Induced Lung Toxicity After Stereotactic Body
Radiation Therapy Using Dose-Volume Parameters From Functional Mapping on Gallium
68 Perfusion Positron Emission Tomography/Computed Tomography.
Int J Radiat Oncol Biol Phys. 2024;118:952-962.
- FAROOQI AS, Yoder AK, Lin HY, Pasalic D, et al
SABR for Sarcoma Lung Metastases: Indications for Treatment and Guidance for
Patient Selection.
Int J Radiat Oncol Biol Phys. 2024;118:971-978.
J Clin Oncol
- HENICK BS, Herzberg BO, Concepcion-Crisol CP, Taylor AM, et al
Controlled Chaos: Parsing Acquired Immunoresistance in Lung Cancer.
J Clin Oncol. 2024 Feb 29:JCO2302339. doi: 10.1200/JCO.23.02339.
- JAIYESIMI IA, Leighl NB, Ismaila N, Alluri K, et al
Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO
Living Guideline, Version 2023.3.
J Clin Oncol. 2024 Feb 28:JCO2302746. doi: 10.1200/JCO.23.02746.
- JAIYESIMI IA, Leighl NB, Ismaila N, Alluri K, et al
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO
Living Guideline, Version 2023.3.
J Clin Oncol. 2024 Feb 28:JCO2302744. doi: 10.1200/JCO.23.02744.
- PIPER VALLILLO AJ, Viray H, Feldman J, Rangachari D, et al
Management of Treatment Resistance in Patients With Advanced Epidermal Growth
Factor Receptor-Mutated Lung Cancer: Personalization, Parsimony, and Partnership.
J Clin Oncol. 2024 Feb 27:JCO2302417. doi: 10.1200/JCO.23.02417.
Lung Cancer
- LEE JD, Zheng R, Okusanya OT, Evans NR 3rd, et al
Association between surgical quality and long-term survival in lung cancer.
Lung Cancer. 2024;190:107511.
- BAR J, Esteban E, Rodriguez-Abreu D, Aix SP, et al
Blood tumor mutational burden and response to pembrolizumab plus chemotherapy in
non-small cell lung cancer: KEYNOTE-782.
Lung Cancer. 2024;190:107506.
Mol Carcinog
- FURUSAWA T, Cavero R, Liu Y, Li H, et al
Metabolism-focused CRISPR screen unveils mitochondrial pyruvate carrier 1 as a
critical driver for PARP inhibitor resistance in lung cancer.
Mol Carcinog. 2024 Feb 27. doi: 10.1002/mc.23705.
Oncogene
- TURKOWSKI K, Herzberg F, Gunther S, Weigert A, et al
miR-147b mediated suppression of DUSP8 promotes lung cancer progression.
Oncogene. 2024 Feb 23. doi: 10.1038/s41388-024-02969.
- GAROFALO M, Quintavalle C, Di Leva G, Zanca C, et al
Editorial Expression of Concern: MicroRNA signatures of TRAIL resistance in human
non-small cell lung cancer.
Oncogene. 2024 Feb 28. doi: 10.1038/s41388-024-02989.
Oncologist
- STRICKER T, Jain N, Ma E, Yu E, et al
Clinical Value of Timely Targeted Therapy for Patients With Advanced Non-Small
Cell Lung Cancer With Actionable Driver Oncogenes.
Oncologist. 2024 Feb 28:oyae022. doi: 10.1093.
PLoS One
- MORI S, Ueki Y, Hasegawa M, Nakamura K, et al
Impact of combined pulmonary fibrosis and emphysema on lung cancer risk and
mortality in rheumatoid arthritis: A multicenter retrospective cohort study.
PLoS One. 2024;19:e0298573.
- WANG H, Tang H, Yuan S, Liang C, et al
IL-17A deficiency inhibits lung cancer-induced osteoclastogenesis by promoting
apoptosis of osteoclast precursor cells.
PLoS One. 2024;19:e0299028.
- YOO SJ, Park YS, Choi H, Kim DS, et al
Prospective evaluation of deep learning image reconstruction for Lung-RADS and
automatic nodule volumetry on ultralow-dose chest CT.
PLoS One. 2024;19:e0297390.
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016